A major milestone in biotechnology has been reached as researchers in Boston have initiated the first human clinical trial of a gene-based anti-aging therapy. Life Biosciences announced on June 9 that the experimental treatment has been safely administered to its first volunteer, marking the beginning of a closely watched study focused on cellular rejuvenation.
The therapy is designed to target aging at the cellular level using a process known as “cellular reprogramming.” It employs Yamanaka factors to partially reset the epigenetic state of cells, aiming to restore them to a more youthful and functional condition without fully reverting them to stem cells. A built-in control system has also been integrated to regulate gene activity and reduce potential risks.
In its initial phase, the treatment is being tested for eye-related disorders, including glaucoma and other vision impairments, where damaged cells may potentially be restored. Researchers emphasize that the trial is still in its early stages, with the primary focus on safety and biological response, but it could open the door to future breakthroughs in age-related disease treatment and longevity science.
